GCM
ORGO icon

Gladius Capital Management’s Organogenesis Holdings ORGO Stock Holding History

Gladius Capital Management’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,645
Closed -$32.6K – 338
2024
Q2 		$32.6K Buy
11,645
+1,415
+14% +$3.8K ﹤0.01% 214
2024
Q1 		$29.1K Buy
+10,230
New +$34.8K 0.01% 296
2023
Q2 		– Sell
-13,833
Closed -$29.5K – 437
2023
Q1 		$29.5K Buy
13,833
+120
+0.9% +$296 ﹤0.01% 288
2022
Q4 		$36.9K Buy
13,713
+3,487
+34% +$10.2K ﹤0.01% 249
2022
Q3 		$34K Buy
+10,226
New +$46.2K ﹤0.01% 275

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gladius Capital Management's ORGO Position: Q3 2024 in Review

Gladius Capital Management sold out of Organogenesis Holdings (ORGO) in Q3 2024, closing a stake of 11,645 shares — an estimated $32.6K sold.

Gladius Capital Management first reported a position in ORGO in Q3 2022 and held it in 5 quarters. The position peaked at $36.9K in Q4 2022. 112 funds tracked by Wall St. Rank hold ORGO as of Q3 2024.

  • Gladius Capital Management reported no remaining Organogenesis Holdings position as of Q3 2024 after selling out during the quarter.
  • Gladius Capital Management sold 11,645 Organogenesis Holdings shares in Q3 2024, an estimated $32.6K.
  • Gladius Capital Management first reported a position in Organogenesis Holdings in Q3 2022 and held it in 5 quarters.
  • Gladius Capital Management's Organogenesis Holdings position peaked at $36.9K in Q4 2022.
  • 112 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q3 2024.

Based on Gladius Capital Management's 13F filing for Q3 2024, filed 6 Nov 2024.